$CRSP insider trading
Over the last 12 months, CRISPR Therapeutics insiders reported no purchases and 19 sales totaling $16.9M across SEC Form 4 filings. 21% of those filings were made under pre-arranged 10b5-1 trading plans.
- Bought · 12m
- — 0 events
- Sold · 12m
- $16.9M 19 events
- Events · 12m
- 19 Form 4 filings, grouped
- Insiders · 12m
- 4 distinct reporters
- 10b5-1 share
- 21% of events, not dollars
All insider trades
Scroll the table sideways for price, value and marks.
| Date | Insider | Type | Shares | Avg price | Value | Δ stake | Marks |
|---|---|---|---|---|---|---|---|
| May 29, 2026 | Patel NaimishChief Medical Officer · O | ▼ Sale | 3,786 | $55.62 | $211K | -16.4% | — |
| Mar 23, 2026 | KASINGER JAMES R.General Counsel and Secretary · O | ▼ Sale | 3,182 | $46.78 | $149K | -3.3% | — |
| Mar 23, 2026 | Kulkarni SamarthChief Executive Officer · O·D | ▼ Sale | 10,020 | $46.78 | $469K | -3.8% | — |
| Mar 23, 2026 | Prasad RajuChief Financial Officer · O | ▼ Sale | 3,708 | $46.78 | $173K | -19.2% | — |
| Mar 16, 2026 | Patel NaimishChief Medical Officer · O | ▼ Sale | 3,150 | $48.26 | $152K | -19.3% | — |
| Mar 16, 2026 | Prasad RajuChief Financial Officer · O | ▼ Sale | 9,869 | $48.26 | $476K | -41.7% | 2 tranches |
| Mar 16, 2026 | KASINGER JAMES R.General Counsel and Secretary · O | ▼ Sale | 3,450 | $48.26 | $166K | -3.6% | — |
| Mar 16, 2026 | Kulkarni SamarthChief Executive Officer · O·D | ▼ Sale | 10,349 | $48.26 | $499K | -4% | — |
| Mar 11, 2026 | KASINGER JAMES R.General Counsel and Secretary · O | ▼ Sale | 2,800 | $52.8 | $148K | -3.1% | — |
| Mar 11, 2026 | Kulkarni SamarthChief Executive Officer · O·D | ▼ Sale | 9,798 | $52.8 | $517K | -4% | — |
| Feb 19, 2026 | Kulkarni SamarthChief Executive Officer · O·D | ▼ Sale | 6,967 | $52.58 | $366K | -3% | — |
| Feb 19, 2026 | KASINGER JAMES R.General Counsel and Secretary · O | ▼ Sale | 2,112 | $52.58 | $111K | -2.4% | — |
| Jan 22, 2026 | Prasad RajuChief Financial Officer · O | ▼ Sale | 34,972 | $60.19 | $2.1M | -83.8% | plan |
| Jan 22, 2026 | Kulkarni SamarthChief Executive Officer · O·D | ▼ Sale | 90,000 | $57.4 | $5.2M | -40.1% | plan · 3 tranches |
| Jan 6, 2026 | Prasad RajuChief Financial Officer · O | ▼ Sale | 29,700 | $60.16 | $1.8M | -81.4% | plan · 3 tranches |
| Dec 22, 2025 | Prasad RajuChief Financial Officer · O | ▼ Sale | 10,000 | $55.95 | $560K | -59.6% | plan · 3 tranches |
| Oct 17, 2025 | Kulkarni SamarthChief Executive Officer · O·D | ▼ Sale | 50,895 | $67.91 | $3.5M | -16.7% | — |
| Oct 14, 2025 | Kulkarni SamarthChief Executive Officer · O·D | ▼ Sale | 4,242 | $66.6 | $283K | -2% | — |
| Oct 14, 2025 | KASINGER JAMES R.General Counsel and Secretary · O | ▼ Sale | 1,076 | $66.6 | $72K | -1.3% | — |
| Aug 18, 2025 | Kulkarni SamarthChief Executive Officer · O·D | ▼ Sale | 13,081 | $58.15 | $761K | -5.9% | — |
| Apr 3, 2025 | Patel NaimishChief Medical Officer · O | ▲ Buy | 1,508 | $32.96 | $50K | — | late |
Every $CRSP filing on this page is one API call away
The same Form 4 data over REST or MCP, already grouped into events with the plan flag and the dollar value read. A free key does 100 calls a day and needs no card. Prefer email? CRISPR Therapeutics filings can reach your inbox instead.
Corporate insiders — officers, directors and 10%+ owners — must report their trades to the SEC on Form 4 within two business days. This page shows open-market activity: purchases (code P), sales (S) and dispositions back to the issuer (D). Scheduled compensation events such as stock grants and option exercises are also filed on Form 4 but carry no trading signal, so they are not shown and counts here can be lower than the raw EDGAR filing total. We group each filing's transactions into one economic event (a laddered 10b5-1 sale is one event, not 25 rows), flag pre-arranged plans and late filings, and link every event to its AI-scored article in the $CRSP feed.